April 5, 2013
/PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that it has secured a new
debt financing facility through a syndicate led by MidCap Financial SBIC, LP ("MidCap Financial"). Anthera will use the loan proceeds to refinance the remaining principal of the loan agreement entered into with Hercules Technology Growth Capital, Inc. in 2011 and for general corporate purposes. MidCap Financial will receive warrants to purchase an aggregate of 588,235 shares of Anthera's common stock at an exercise price of
"The favorable terms of the new debt financing facility, coupled with our
equity financing of approximately
of net proceeds, provides the liquidity we need to deliver key milestones for 2013 and 2014," said
, Anthera's Chief Business Officer and Chief Financial Officer.
Additionally, Anthera has entered into an
common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC") a
-based institutional investor. Upon executing the agreement, LPC made an initial purchase of
in common stock from Anthera at a purchase price of
per share. Furthermore, for a period of two years, Anthera has the right to sell up to an additional
of its common stock to LPC at prices that are generally determined by the Company. Anthera expects to use the proceeds from this transaction for servicing long-term debt and working capital.
Under the terms of the agreement, there are no upper limits to the price that LPC may pay to purchase Anthera's common stock. Anthera will control the timing of any future sales and the amount of shares to be sold. LPC has no right to require any sales and is obligated to purchase the common stock as directed by Anthera. Under the terms of the agreement, LPC has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Anthera's shares of common stock. In consideration for entering into the agreement, Anthera may issue up to 898,059 of additional shares to LPC as a commitment fee, depending upon the actual amount drawn from the equity line. The shares covered under the agreement are the subject of a prospectus supplement pursuant to Anthera's effective shelf registration statement and base prospectus contained therein.